Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
493
datasets available to search
ShareScore release 0.9.0
Dataset results
493 results for “human breast cancer”
Vinflunine Plus Trastuzumab in Human Epidermal Growth Factor Receptor 2 (HER2neu) Over-Expressing Metastatic Breast Cancer
ClinicalTrials.gov study NCT00284180. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Talazoparib For Neoadjuvant Treatment Of Germline BRCA1/2 Mutation Patients With Early Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer
ClinicalTrials.gov study NCT03499353. IPD Sharing: YES. Countries: 1. Publications: 2.
Afatinib (BIBW2992) in HER2 (Human Epidermal Growth Factor Receptor 2)-Overexpressing Inflammatory Breast Cancer
ClinicalTrials.gov study NCT01325428. IPD Sharing: Not stated. Countries: 7. Publications: 1.
A Combination Study of Kadcyla (Trastuzumab Emtansine) and Capecitabine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (mBC) or HER2-Positive Lo
ClinicalTrials.gov study NCT01702558. IPD Sharing: Not stated. Countries: 12. Publications: 1.
Herceptin (Trastuzumab) in Treating Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Primary Breast Cancer
ClinicalTrials.gov study NCT00045032. IPD Sharing: Not stated. Countries: 33. Publications: 18.
A Study to Compare Subcutaneous (SC) Versus Intravenous (IV) Administration of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer
ClinicalTrials.gov study NCT00950300. IPD Sharing: Not stated. Countries: 26. Publications: 2.
A Study of Pertuzumab With High-Dose Trastuzumab for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC) With Central Nervous System (CNS) Progress
ClinicalTrials.gov study NCT02536339. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Data from: Mannose glycosylation is an integral step for human NIS localization and function in breast cancer cells
Open the record for dataset details and reuse information.
Fig. 7 in Ethanolic extract of Mimosa caesalpiniifolia leaves: Chemical characterization and cytotoxic effect on human breast cancer MCF-7 cell line
Fig. 7. Agarose gel electrophoresis of MCF-7 cell genomic DNA. 1, ladder marker; 2, negative control; 3, cyclophosphamide (CP)-treated; 4–7, ethanolic extracts of Mimosa caesalpiniifolia leaves (EEM) in different concentrations (5.0; 20.0; 160.0 and 320.0 μg/mL). The results are representative of three independent experiments carried out in the same conditions. DNA ladder formation indicates apoptosis as seen in lanes 3–7.
Fig. 6. MCF-7 in Ethanolic extract of Mimosa caesalpiniifolia leaves: Chemical characterization and cytotoxic effect on human breast cancer MCF-7 cell line
Fig. 6. MCF-7 cell death (%) after treatment with cyclophosphamide (CP, 550 μg/mL) and different concentrations (5.0–320.0 μg/mL) of the ethanolic extract of Mimosa caesalpiniifolia leaves (EEM) for 24 h, compared to the negative control cells (NC), estimated by the Fast green color dye exclusion. Results are expressed as mean ± SEM of three independent experiments. Different letters indicate significant differences (p <0.01) by the Tukey test. Inset: appearance of cells after fast green-hematoxylin–eosin staining; 1, living cell; 2, green dead cell. EEM treatment kills MCF-7 cells in a concentrationdependent manner.
Fig. 3 in Ethanolic extract of Mimosa caesalpiniifolia leaves: Chemical characterization and cytotoxic effect on human breast cancer MCF-7 cell line
Fig. 3. Morphology of MCF-7 cells stained with hematoxylin–eosin, after 24 and 48 h incubation. NC, negative control cells; CP, cells treated with 550 μg/mL cyclophosphamide; 5, 80 and 320, cells treated, respectively, with 5.0, 80.0 and 320.0 μg/mL ethanolic extract of Mimosa caenalpiniifolia leaves. All the pictures are typical of three independent experiments, each carried out under identical conditions. Bar = 5 μm. Arrow—nucleolus; R—rounding; CC—chromatin condensation.
Fig. 2. MCF-7 in Ethanolic extract of Mimosa caesalpiniifolia leaves: Chemical characterization and cytotoxic effect on human breast cancer MCF-7 cell line
Fig. 2. MCF-7 cell protein content decreasing (%), estimated by the sulforhodamine B assay, after treatment with cyclophosphamide (CP, 550 μg/mL) and different concentrations of the ethanolic extract of Mimosa caesalpiniifolia leaves (EEM 5.0 - 320.0 μg/mL) for 24 and 48 h. The results are expressed as mean ± SEM of three independent experiments. Different letters indicate significant differences (p <0.001) by the Tukey test. Protein content was calculated relative to the negative control and 320.0 μg/mL EEM produced the maximum effect.
Fig. 1 in Ethanolic extract of Mimosa caesalpiniifolia leaves: Chemical characterization and cytotoxic effect on human breast cancer MCF-7 cell line
Fig. 1. HPLC-DAD-ESI-MS analysis of the ethanolic extract of Mimosa caesalpiniifolia leaves. (A) UV 360 nm; (B) ESI-MS, base peak chromatogram, negative ion mode, m/z 100–1500. No additional peaks were detected when the UV trace was recorded at wavelengths down to 360 nm. Peaks assigned as m/z: 288.97, 318.00, and 576.77 were identified, respectively, as catechin, 2,3 dihydroquercetagetin, and procyanidin B2 [(epi)catechin–(epi)catechin)] (see structures).
Fig. 4. MCF-7 in Ethanolic extract of Mimosa caesalpiniifolia leaves: Chemical characterization and cytotoxic effect on human breast cancer MCF-7 cell line
Fig. 4. MCF-7 cell diameter (μm) after treatment with cyclophosphamide (CP, 550 μg/mL) and different concentrations (5.0–320.0 μg/mL) of the ethanolic extract of Mimosa caesalpiniifolia leaves (EEM) for 24 or 48 h, compared to the negative control cells (NC). Results are expressed as mean ± SEM of three independent experiments. Different letters indicate significant differences (p <0.01) by the Tukey test. Note cell-diameter reduction after treatment, in comparison to the negative control cells, thereby indicating EEM cytotoxicity.
A Study of Bevacizumab (Avastin) in Combination With Neoadjuvant Treatment Regimens in Participants With Primary Human Epidermal Growth Factor Receptor 2 (HER2) Negative Breast Cancer
ClinicalTrials.gov study NCT00773695. IPD Sharing: Not stated. Countries: 1. Publications: 3.
A Study to Assess Preference for Subcutaneous Trastuzumab Treatment in Participants With Human Epidermal Growth Factor Receptor (HER)2-Positive Metastatic Breast Cancer Responding to First-Line Intrav
ClinicalTrials.gov study NCT01810393. IPD Sharing: Not stated. Countries: 1. Publications: 1.
First-in-human, Study of MATTISSE® Tissue Engineering Chamber in Adult Female Patients Undergoing Breast Reconstruction After Mastectomy for Cancer
ClinicalTrials.gov study NCT05460780. IPD Sharing: NO. Countries: 2. Publications: 20.
Weekly Gemcitabine and Trastuzumab in the Treatment of Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Metastatic Breast Cancer
ClinicalTrials.gov study NCT00193063. IPD Sharing: Not stated. Countries: 0. Publications: 1.
A Study to Evaluate Lumretuzumab in Combination With Pertuzumab and Paclitaxel in Participants With Metastatic Breast Cancer Expressing Human Epidermal Growth Factor Receptor (HER) 3 and HER2 Protein
ClinicalTrials.gov study NCT01918254. IPD Sharing: Not stated. Countries: 4. Publications: 1.
Human Epidermal Growth Factor Receptor 2 (HER2) Positive Unresectable Locally Advanced or Metastatic Breast Cancer Disease Registry Study
ClinicalTrials.gov study NCT02393924. IPD Sharing: Not stated. Countries: 1. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.